New Antivirals against Coronaviruses
A special issue of COVID (ISSN 2673-8112).
Deadline for manuscript submissions: 28 February 2025 | Viewed by 201
Special Issue Editor
Special Issue Information
Dear Colleagues,
After four years of the SARS-CoV-2 outbreak that led to the most recent pandemic, COVID-19 continues to be a human threat, especially in susceptible populations. According to the CDC, as of June 2024, nearly 1.2 million people have died of COVID-19 only in the U.S. Currently, a few vaccine options and antivirals authorized or approved by the FDA are available for the prophylaxis and disease treatment, including Paxlovid, Veklury, and Lagrevio as the most common drugs used. However, vaccines need to be updated as the SARS-CoV-2 virus is continuously changing, and the undesired side effects and the occurrence of drug–drug interactions represent key disadvantages for some of the existing antivirals.
The understanding of the current treatment limitations as well as the virus pathogenicity and escape mechanisms led to the discovery of new antivirals against coronaviruses, and candidates with good potentialities are advancing in different stages of development. The battle continues as new SARS-CoV-2 variants are emerging and new efforts are needed to fight the increased transmissibility and immune evasion exhibited by the circulating subvariants. The most recent reports highlight KP.3.1.1 (a new Omicron JN.1 subvariant) as the most prevalent VoC, accounting for nearly 30% of the current reported cases.
The aim of this Special Issue is to gather articles (research articles, short communications, and reviews) to visualize and contribute to broadcast the recent advances in the discovery and development of new antiviral candidates as well as innovative therapies for coronaviruses, including nanotechnologies, monoclonal antibodies, genome editing, and other alternatives directed to inhibit viral replication.
Dr. Nadine Alvarez
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. COVID is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antivirals
- SARS-CoV-2
- coronaviruses
- broad-spectrum
- pan-coronavirus inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
